Bacon P A
Faculty of Medicine, Department of Rheumatology, University of Birmingham, Edgbaston, UK.
Eur J Rheumatol Inflamm. 1994;14(1):19-22.
A growing proportion of patients who require nonsteroidal anti-inflammatory drug (NSAID) therapy are elderly. Data from patients 65 years and older with osteoarthritis or rheumatoid arthritis show that etodolac is as well tolerated in elderly as in younger patients. Of 273 elderly patients treated with at least 600 mg daily, only 12% withdrew because of adverse events, a rate similar to that in the younger age-group. Notably, the incidence of etodolac-associated gastrointestinal events is no higher in elderly than in younger patients. Etodolac was no different from diclofenac and piroxicam regarding incidence and type of adverse events. In both short- and long-term studies, the 400-mg and 600-mg sustained-release etodolac formulations were well tolerated in elderly and younger patients. Thus, etodolac appears to be a first-line choice in elderly patients.
需要非甾体抗炎药（NSAID）治疗的患者中，老年患者的比例正在增加。来自65岁及以上骨关节炎或类风湿关节炎患者的数据表明，依托度酸在老年患者中的耐受性与年轻患者相当。在273例每日至少服用600mg依托度酸的老年患者中，仅有12%因不良事件而停药，这一比例与年轻患者组相似。值得注意的是，依托度酸相关胃肠道事件的发生率在老年患者中并不高于年轻患者。在不良事件的发生率和类型方面，依托度酸与双氯芬酸和吡罗昔康并无差异。在短期和长期研究中，400mg和600mg的依托度酸缓释制剂在老年和年轻患者中均耐受性良好。因此，依托度酸似乎是老年患者的一线选择。
